|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US7491805B2
(en)
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
|
US8546143B2
(en)
|
2001-01-09 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
US20050171040A1
(en)
*
|
2001-05-18 |
2005-08-04 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CEPT) gene expression using short interfering nucleic acid (siNA)
|
|
US20050261219A1
(en)
*
|
2001-05-18 |
2005-11-24 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
|
|
US7517864B2
(en)
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
|
DE10163098B4
(de)
|
2001-10-12 |
2005-06-02 |
Alnylam Europe Ag |
Verfahren zur Hemmung der Replikation von Viren
|
|
DE10202419A1
(de)
|
2002-01-22 |
2003-08-07 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
|
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
GB0212303D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Molecular targetting of IGF-1 receptor
|
|
GB0212302D0
(en)
*
|
2002-05-28 |
2002-07-10 |
Isis Innovation |
Method of selecting targets for gene silencing by RNA interference
|
|
US7452987B2
(en)
|
2002-08-05 |
2008-11-18 |
Silence Therapeutics Aktiengesellschaft (Ag) |
Interfering RNA molecules
|
|
US8729036B2
(en)
|
2002-08-07 |
2014-05-20 |
University Of Massachusetts |
Compositions for RNA interference and methods of use thereof
|
|
CA2881743A1
(en)
|
2002-09-25 |
2004-04-08 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
US9827263B2
(en)
|
2002-11-05 |
2017-11-28 |
Ionis Pharmaceuticals, Inc. |
2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
|
US7612196B2
(en)
|
2002-11-14 |
2009-11-03 |
Dharmacon, Inc. |
siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
|
|
US7635770B2
(en)
|
2002-11-14 |
2009-12-22 |
Dharmacon, Inc. |
siRNA targeting protein kinase N-3 (PKN-3)
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
EP2213738B1
(en)
|
2002-11-14 |
2012-10-10 |
Dharmacon, Inc. |
siRNA molecules targeting Bcl-2
|
|
US7977471B2
(en)
|
2002-11-14 |
2011-07-12 |
Dharmacon, Inc. |
siRNA targeting TNFα
|
|
US7592442B2
(en)
|
2002-11-14 |
2009-09-22 |
Dharmacon, Inc. |
siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
|
|
US7619081B2
(en)
|
2002-11-14 |
2009-11-17 |
Dharmacon, Inc. |
siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
|
|
US10011836B2
(en)
|
2002-11-14 |
2018-07-03 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9719092B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting CNTD2
|
|
US9771586B2
(en)
|
2002-11-14 |
2017-09-26 |
Thermo Fisher Scientific Inc. |
RNAi targeting ZNF205
|
|
US8163896B1
(en)
|
2002-11-14 |
2012-04-24 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US7691998B2
(en)
|
2002-11-14 |
2010-04-06 |
Dharmacon, Inc. |
siRNA targeting nucleoporin 62kDa (Nup62)
|
|
US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US7250496B2
(en)
|
2002-11-14 |
2007-07-31 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory genes and uses thereof
|
|
US9719094B2
(en)
|
2002-11-14 |
2017-08-01 |
Thermo Fisher Scientific Inc. |
RNAi targeting SEC61G
|
|
US7951935B2
(en)
|
2002-11-14 |
2011-05-31 |
Dharmacon, Inc. |
siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
|
|
US9839649B2
(en)
|
2002-11-14 |
2017-12-12 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US9879266B2
(en)
|
2002-11-14 |
2018-01-30 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
|
US8198427B1
(en)
|
2002-11-14 |
2012-06-12 |
Dharmacon, Inc. |
SiRNA targeting catenin, beta-1 (CTNNB1)
|
|
US7790867B2
(en)
|
2002-12-05 |
2010-09-07 |
Rosetta Genomics Inc. |
Vaccinia virus-related nucleic acids and microRNA
|
|
AU2004204068B8
(en)
*
|
2003-01-03 |
2010-03-25 |
Gencia Corporation |
SiRNA Mediated Post - Transcriptional Gene Silencing of Genes involved in Alopecia
|
|
BRPI0407107A
(pt)
*
|
2003-01-31 |
2006-01-24 |
Novartis Ag |
Infra-regulação de gene alvo com complexos de oligoribonucleotìdeo de filamento único e polìmero de polietilenoimina (pei)
|
|
EP2239329A1
(en)
|
2003-03-07 |
2010-10-13 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
|
DK1606406T4
(da)
|
2003-03-21 |
2013-12-16 |
Santaris Pharma As |
Short Interfering RNA (siRNA) Analogues
|
|
AU2004227414A1
(en)
*
|
2003-04-03 |
2004-10-21 |
Alnylam Pharmaceuticals |
iRNA conjugates
|
|
US7541442B2
(en)
|
2003-05-30 |
2009-06-02 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
|
AU2004263823B2
(en)
|
2003-05-30 |
2008-09-18 |
Agensys, Inc. |
Prostate stem cell antigen (PSCA) variants and subsequences thereof
|
|
US7595379B2
(en)
|
2003-05-30 |
2009-09-29 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
|
US7888497B2
(en)
|
2003-08-13 |
2011-02-15 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
|
US7294704B2
(en)
|
2003-08-15 |
2007-11-13 |
Diadexus, Inc. |
Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
|
|
AU2004269150C1
(en)
|
2003-08-28 |
2010-11-18 |
Novartis Ag |
Interfering RNA duplex having blunt-ends and 3'-modifications
|
|
WO2005045035A2
(en)
*
|
2003-10-23 |
2005-05-19 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
EP1526177A1
(en)
|
2003-10-24 |
2005-04-27 |
Institut Curie |
Nucleic acids useful for triggering tumor cell lethality
|
|
US7476729B2
(en)
|
2003-10-24 |
2009-01-13 |
Institut Curie |
Dbait and uses thereof
|
|
US20050191653A1
(en)
*
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
|
US20070275918A1
(en)
*
|
2003-11-07 |
2007-11-29 |
The Board Of Trustees Of The University Of Illinois |
Induction of Cellular Senescence by Cdk4 Disruption for Tumor Suppression and Regression
|
|
SE0303397D0
(sv)
*
|
2003-12-17 |
2003-12-17 |
Index Pharmaceuticals Ab |
Compounds and method for RNA interference
|
|
ATE491715T1
(de)
|
2004-01-30 |
2011-01-15 |
Quark Pharmaceuticals Inc |
Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
|
|
EP2123759B1
(en)
*
|
2004-02-06 |
2014-01-15 |
Thermo Fisher Scientific Biosciences Inc. |
Stabilized RNAS as transfection controls and silencing reagents
|
|
ATE452188T1
(de)
|
2004-02-10 |
2010-01-15 |
Sirna Therapeutics Inc |
Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
|
|
AU2005222902B2
(en)
|
2004-03-12 |
2010-06-10 |
Alnylam Pharmaceuticals, Inc. |
iRNA agents targeting VEGF
|
|
US20080199438A1
(en)
*
|
2004-03-16 |
2008-08-21 |
Dnavec Research Inc. |
Methods For Suppressing Tumor Proliferation
|
|
JP2007530431A
(ja)
*
|
2004-03-24 |
2007-11-01 |
オンコセラピー・サイエンス株式会社 |
膵臓癌を治療するための組成物および方法
|
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
EP2481802B1
(en)
*
|
2004-04-09 |
2015-06-10 |
Genecare Research Institute Co., Ltd |
Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
|
|
EP1747022A4
(en)
|
2004-04-23 |
2010-03-31 |
Univ Columbia |
INHIBITION OF HAIRLESS PROTEIN MRNA
|
|
WO2005108572A1
(de)
*
|
2004-05-06 |
2005-11-17 |
Medizinische Hochschule Hannover |
Verbindungen und verfahren zur immunsuppression
|
|
US7605250B2
(en)
|
2004-05-12 |
2009-10-20 |
Dharmacon, Inc. |
siRNA targeting cAMP-specific phosphodiesterase 4D
|
|
US7687616B1
(en)
|
2004-05-14 |
2010-03-30 |
Rosetta Genomics Ltd |
Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
|
|
IL179285A
(en)
|
2004-05-14 |
2011-04-28 |
Rosetta Genomics Ltd |
Micrornas and uses thereof
|
|
DE102004025881A1
(de)
|
2004-05-19 |
2006-01-05 |
Beiersdorf Ag |
Oligoribonukleotide zur Beeinflussung des Haarwachstums
|
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
|
US7795419B2
(en)
|
2004-05-26 |
2010-09-14 |
Rosetta Genomics Ltd. |
Viral and viral associated miRNAs and uses thereof
|
|
KR101094617B1
(ko)
|
2004-08-16 |
2011-12-15 |
사일런스 테라퓨틱스 아게 |
알티피801 억제제의 치료적 용도
|
|
SI1781787T1
(sl)
|
2004-08-23 |
2017-08-31 |
Sylentis S.A.U. |
Zdravljenje očesnih nepravilnosti, kakakterističnih za povišan očesni tlak s sirna
|
|
RU2410430C2
(ru)
*
|
2004-08-31 |
2011-01-27 |
Силентис С.А.У. |
Способы и композиции для ингибирования экспрессии рецептора p2х7
|
|
KR101409241B1
(ko)
|
2004-09-28 |
2014-06-24 |
쿠아크 파마수티칼스 인코퍼레이티드 |
탈모증, 급성신부전증 및 다른 질환의 치료를 위한 올리고리보뉴클레오티드 및 그것의 사용방법
|
|
US20090209619A1
(en)
*
|
2004-10-14 |
2009-08-20 |
Zhiguo Wang |
Depression of herg k+ channel function in mammallan cells and applications to the control of cancer cells division
|
|
US20060253100A1
(en)
|
2004-10-22 |
2006-11-09 |
Medtronic, Inc. |
Systems and Methods to Treat Pain Locally
|
|
WO2006050475A2
(en)
|
2004-11-03 |
2006-05-11 |
Brigham And Women's Hospital, Inc. |
Identification of dysregulated genes in patients with neurological diseases
|
|
KR100780548B1
(ko)
|
2004-12-08 |
2007-11-29 |
한국원자력연구원 |
Ｓ-아데노실 메티오닌 디카르복실라제 ｍＲＮＡ에특이적인 작은 간섭 ＲＮＡ 및 그를 유효성분으로포함하는 악성종양 치료제
|
|
CA2589406A1
(en)
|
2004-12-09 |
2006-06-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas
|
|
AU2011203218B2
(en)
*
|
2004-12-09 |
2013-02-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
|
|
EP2316942B1
(en)
*
|
2004-12-22 |
2021-04-21 |
Alnylam Pharmaceuticals, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
|
DK1830888T3
(en)
|
2004-12-27 |
2015-10-19 |
Silence Therapeutics Gmbh |
LIPID COMPLEX COATED WITH PEG AND APPLICATION THEREOF
|
|
US8227591B2
(en)
*
|
2005-03-02 |
2012-07-24 |
National Institute Of Immunology |
Nucleotide sequences
|
|
GB0505081D0
(en)
|
2005-03-14 |
2005-04-20 |
Genomica Sau |
Downregulation of interleukin-12 expression by means of rnai technology
|
|
EP1873240B1
(en)
*
|
2005-04-15 |
2011-12-28 |
National University Corporation Tottori University |
hTERT GENE EXPRESSION REGULATORY GENE
|
|
KR20060119412A
(ko)
*
|
2005-05-20 |
2006-11-24 |
아주대학교산학협력단 |
ＩＬ-6 발현 억제를 위한 ｓｉＲＮＡ 및 이를 함유하는조성물
|
|
JP5176104B2
(ja)
*
|
2005-07-15 |
2013-04-03 |
国立大学法人名古屋大学 |
エレクトロポレーション装置の制御方法
|
|
US7919583B2
(en)
|
2005-08-08 |
2011-04-05 |
Discovery Genomics, Inc. |
Integration-site directed vector systems
|
|
MX2008002369A
(es)
*
|
2005-08-17 |
2008-03-18 |
Sirna Therapeutics Inc |
Moleculas cortas de acidos nucleicos de interferencia quimicamente modificadas que actuan de mediadoras de la interferencia del acido ribonucleico.
|
|
GB0521351D0
(en)
|
2005-10-20 |
2005-11-30 |
Genomica Sau |
Modulation of TRPV expression levels
|
|
GB0521716D0
(en)
|
2005-10-25 |
2005-11-30 |
Genomica Sau |
Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
|
|
US20080090775A1
(en)
*
|
2005-10-31 |
2008-04-17 |
Chong Huang |
Antagonist of TEB4 and Methods of Use
|
|
US8101741B2
(en)
|
2005-11-02 |
2012-01-24 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
BRPI0620723A2
(pt)
*
|
2005-12-29 |
2011-11-22 |
Alcon Res Ltd |
inibição de igf1r mediada por rnai para tratamento de angiogênese ocular
|
|
DOP2007000015A
(es)
|
2006-01-20 |
2007-08-31 |
Quark Biotech Inc |
Usos terapéuticos de inhibidores de rtp801
|
|
US7825099B2
(en)
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
US7910566B2
(en)
|
2006-03-09 |
2011-03-22 |
Quark Pharmaceuticals Inc. |
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
|
|
GB0605337D0
(en)
|
2006-03-17 |
2006-04-26 |
Genomica Sau |
Treatment of CNS conditions
|
|
WO2007107162A2
(en)
|
2006-03-23 |
2007-09-27 |
Santaris Pharma A/S |
Small internally segmented interfering rna
|
|
MX2008012219A
(es)
*
|
2006-04-03 |
2008-10-02 |
Santaris Pharma As |
Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn.
|
|
GB0608838D0
(en)
|
2006-05-04 |
2006-06-14 |
Novartis Ag |
Organic compounds
|
|
US8399424B2
(en)
|
2006-06-08 |
2013-03-19 |
Amino Up Chemical Co., Ltd |
Method for controlling the amount of gene product, and agent for controlling the amount of gene product
|
|
NZ574034A
(en)
|
2006-06-08 |
2011-09-30 |
Amino Up Chemical Co Ltd |
SENSE OLIGONUCLEOTIDE CAPABLE OF CONTROLLING THE EXPRESSION OF iNOS AND COMPOSITION COMPRISING THE SAME
|
|
US7915399B2
(en)
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
|
WO2007141796A2
(en)
|
2006-06-09 |
2007-12-13 |
Quark Pharmaceuticals, Inc. |
Therapeutic uses of inhibitors of rtp801l
|
|
EP2423332A1
(en)
|
2006-08-25 |
2012-02-29 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
|
CA2662843A1
(en)
*
|
2006-09-07 |
2008-03-13 |
Universidad De Salamanca |
Identification of cancer stem cells using genetic markers
|
|
CA2666657A1
(en)
*
|
2006-10-18 |
2008-04-24 |
Nastech Pharmaceutical Company Inc. |
Nicked or gapped nucleic acid molecules and uses thereof
|
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のｓｉＲＮＡおよびその使用方法
|
|
US20100009920A1
(en)
|
2006-12-13 |
2010-01-14 |
Yusuke Nakamura |
Ttk as tumor marker and therapeutic target for lung cancer
|
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
|
JP2010518880A
(ja)
|
2007-02-26 |
2010-06-03 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
Ｒｔｐ８０１のインヒビター及びその疾患の治療における使用
|
|
WO2008109492A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting igf1r gene expression and uses thereof
|
|
WO2008109454A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting fos gene expression and uses thereof
|
|
WO2008109359A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting pdgfr family gene expression and uses thereof
|
|
WO2008109378A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting pdgfr gene expression and uses thereof
|
|
US7812002B2
(en)
|
2007-03-21 |
2010-10-12 |
Quark Pharmaceuticals, Inc. |
Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
|
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
|
JP5296328B2
(ja)
|
2007-05-09 |
2013-09-25 |
独立行政法人理化学研究所 |
１本鎖環状ｒｎａおよびその製造方法
|
|
DK2170403T3
(da)
|
2007-06-27 |
2014-06-16 |
Quark Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til hæmning af ekspressionen af proapoptotiske gener
|
|
WO2009021150A2
(en)
*
|
2007-08-08 |
2009-02-12 |
California Pacific Medical Center |
Platelet derived growth factor receptor supports cytomegalovirus infectivity
|
|
EP2187900B1
(en)
|
2007-08-16 |
2016-11-09 |
The Schepens Eye Research Institute, Inc. |
Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
|
|
BRPI0816150A2
(pt)
|
2007-08-24 |
2019-09-24 |
Oncotherapy Science Inc |
genes relacionados com câncer, cdca5, eph47, stk31 e w-dhd1.
|
|
CA2697512A1
(en)
|
2007-08-24 |
2009-03-05 |
Oncotherapy Science, Inc. |
Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis
|
|
JP5723154B2
(ja)
|
2007-09-19 |
2015-05-27 |
アプライド バイオシステムズ リミテッド ライアビリティー カンパニー |
ＲＮＡｉにおけるオフターゲット表現型の影響を減少させるためのＳｉＲＮＡ配列非依存性修飾フォーマットおよびその安定化型
|
|
ES2647538T3
(es)
|
2007-09-28 |
2017-12-22 |
Pfizer Inc. |
Direccionamiento a células de cáncer usando nanopartículas
|
|
US8614309B2
(en)
*
|
2007-10-03 |
2013-12-24 |
Quark Pharmaceuticals, Inc. |
Double-stranded RNA directed to CASP2 and methods of use thereof
|
|
WO2009074076A1
(en)
*
|
2007-11-29 |
2009-06-18 |
Suzhou Ribo Life Science Co., Ltd |
A complex molecule interfering the expression of target genes and its preparing methods
|
|
US9006191B2
(en)
|
2007-12-27 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering RNA
|
|
CA3069576A1
(en)
|
2008-01-09 |
2009-07-16 |
The Schepens Eye Research Institute, Inc. |
Therapeutic compositions for treatment of ocular inflammatory disorders
|
|
JP5346957B2
(ja)
|
2008-01-23 |
2013-11-20 |
ヘルレフ ホスピタル |
不特定疾患の汎用マーカーとしてのｙｋｌ−４０
|
|
EP2264167B1
(en)
*
|
2008-03-31 |
2016-10-12 |
National Institute of Advanced Industrial Science and Technology |
Double-stranded lipid-modified rna having high rna interference effect
|
|
EP2281041B1
(en)
|
2008-04-15 |
2014-07-02 |
Protiva Biotherapeutics Inc. |
Silencing of csn5 gene expression using interfering rna
|
|
CA2721333C
(en)
|
2008-04-15 |
2020-12-01 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for nucleic acid delivery
|
|
US8278287B2
(en)
|
2008-04-15 |
2012-10-02 |
Quark Pharmaceuticals Inc. |
siRNA compounds for inhibiting NRF2
|
|
USRE48948E1
(en)
|
2008-04-18 |
2022-03-01 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable polymer
|
|
WO2009131733A1
(en)
*
|
2008-04-21 |
2009-10-29 |
The Trustees Of Columbia University In The City Of New York |
Gab2 amplification in melanoma
|
|
EP2293800B1
(en)
|
2008-06-06 |
2016-10-05 |
Quark Pharmaceuticals, Inc. |
Compositions and methods for treatment of ear disorders
|
|
WO2010008562A2
(en)
|
2008-07-16 |
2010-01-21 |
Recombinetics |
Methods and materials for producing transgenic animals
|
|
JP5764822B2
(ja)
|
2008-08-27 |
2015-08-19 |
オンコセラピー・サイエンス株式会社 |
がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
|
|
WO2010028658A1
(en)
|
2008-09-15 |
2010-03-18 |
Herlev Hospital, Region Hovedstaden |
Ykl-40 as a marker for gastrointestinal cancers
|
|
JP2011251912A
(ja)
*
|
2008-09-22 |
2011-12-15 |
Gifu Prefecture Kenkyu Kaihatsu Zaidan |
マイクロｒｎａ―１４３誘導体を含有する医薬
|
|
US20100239632A1
(en)
|
2009-03-23 |
2010-09-23 |
Warsaw Orthopedic, Inc. |
Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
|
|
WO2011019423A2
(en)
|
2009-05-20 |
2011-02-17 |
Schering Corporation |
Modulation of pilr receptors to treat microbial infections
|
|
JP6128846B2
(ja)
*
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ（ｐｏｎ１）に対する天然アンチセンス転写物の抑制によるｐｏｎ１遺伝子関連疾患の治療
|
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
|
WO2011011447A1
(en)
|
2009-07-20 |
2011-01-27 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing ebola virus gene expression
|
|
EP2475388B1
(en)
|
2009-09-10 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Use of il-33 antagonists to treat fibrotic disease
|
|
WO2011038160A2
(en)
|
2009-09-23 |
2011-03-31 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes expressed in cancer
|
|
EP2504435B1
(en)
|
2009-11-26 |
2019-11-13 |
Quark Pharmaceuticals, Inc. |
Sirna compounds comprising terminal substitutions
|
|
WO2011084357A1
(en)
|
2009-12-17 |
2011-07-14 |
Schering Corporation |
Modulation of pilr to treat immune disorders
|
|
WO2011084193A1
(en)
|
2010-01-07 |
2011-07-14 |
Quark Pharmaceuticals, Inc. |
Oligonucleotide compounds comprising non-nucleotide overhangs
|
|
CN101787366B
(zh)
*
|
2010-03-04 |
2012-09-19 |
中国人民解放军军事医学科学院放射与辐射医学研究所 |
一种特异抑制Rab27B基因表达的DNA片段及其应用
|
|
CA2804847A1
(en)
|
2010-07-28 |
2012-02-02 |
Alcon Research Ltd. |
Sirna targeting vegfa and methods for treatment in vivo
|
|
LT2606134T
(lt)
|
2010-08-17 |
2019-07-25 |
Sirna Therapeutics, Inc. |
Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
|
|
KR20130137160A
(ko)
|
2010-08-24 |
2013-12-16 |
머크 샤프 앤드 돔 코포레이션 |
내부의 비－핵산 스페이서를 함유하는 단일－가닥 ＲＮＡｉ 작용제
|
|
EP2611933A1
(en)
*
|
2010-09-02 |
2013-07-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for the prognosis of the progression of cancer
|
|
EP2433644A1
(en)
|
2010-09-22 |
2012-03-28 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Breast cancer therapeutics
|
|
EP2632472B1
(en)
|
2010-10-29 |
2017-12-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
|
JPWO2012063894A1
(ja)
|
2010-11-12 |
2014-05-12 |
国立大学法人愛媛大学 |
マイクロｒｎａのアンチセンスオリゴヌクレオチドを含む組成物
|
|
WO2012106556A2
(en)
|
2011-02-02 |
2012-08-09 |
Amgen Inc. |
Methods and compositons relating to inhibition of igf-1r
|
|
EP2723349A4
(en)
*
|
2011-06-27 |
2015-01-14 |
Medimmune Llc |
MICROARN-31 COMPOSITIONS AND METHODS OF USE IN AUTOIMMUNE DISEASES
|
|
TW202244278A
(zh)
|
2011-06-30 |
2022-11-16 |
美商艾羅海德製藥公司 |
用於抑制ｂ型肝炎病毒基因表現之組合物及方法
|
|
WO2013010045A1
(en)
|
2011-07-12 |
2013-01-17 |
Biotime Inc. |
Novel methods and formulations for orthopedic cell therapy
|
|
US20140243391A1
(en)
|
2011-07-22 |
2014-08-28 |
Centre National De La Recherche Scientifique |
Phospholipid-detergent conjugates and uses thereof
|
|
WO2013071022A1
(en)
*
|
2011-11-10 |
2013-05-16 |
Shire Human Genetic Therapies, Inc. |
Antisense oligonucleotide modulators of serotonin receptor 2c and uses thereof
|
|
US9700619B2
(en)
|
2011-11-11 |
2017-07-11 |
Duke University |
Combination drug therapy for the treatment of solid tumors
|
|
FI3366775T4
(fi)
*
|
2011-11-18 |
2025-11-14 |
Alnylam Pharmaceuticals Inc |
Modifioituja rnai-agensseja
|
|
PT2817287T
(pt)
|
2012-02-24 |
2018-12-28 |
Arbutus Biopharma Corp |
Lípidos catiónicos trialquílicos e seus métodos de utilização
|
|
WO2013134766A2
(en)
*
|
2012-03-09 |
2013-09-12 |
The Johns Hopkins University |
Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disorders
|
|
TWI480043B
(zh)
*
|
2012-05-01 |
2015-04-11 |
Univ Kaohsiung Medical |
用以治療塑化劑引發之雌激素受體陰性型乳癌的醫藥組成物
|
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
US9434951B2
(en)
*
|
2012-05-22 |
2016-09-06 |
University Of Massachusetts |
Compositions and methods for decreasing leukocyte extravasation and vessel fluid leakage
|
|
WO2013192233A1
(en)
*
|
2012-06-18 |
2013-12-27 |
Isis Pharmaceuticals, Inc. |
Compounds and method for improved cellular uptake of antisense compounds
|
|
US8980259B2
(en)
|
2012-07-20 |
2015-03-17 |
Novartis Ag |
Combination therapy
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
EP2700949A1
(en)
|
2012-08-24 |
2014-02-26 |
IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. |
Use of biliverdin reductase proteins as cancer marker
|
|
KR102120060B1
(ko)
|
2012-09-05 |
2020-06-09 |
실렌티스 에스.에이.유. |
눈 컨디션의 치료 및/또는 예방을 위한 조성물 및 방법에 있어서 siRNA 및 이의 용도
|
|
GB201215857D0
(en)
|
2012-09-05 |
2012-10-24 |
Sylentis Sau |
siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
CA2882975C
(en)
|
2012-09-06 |
2022-08-23 |
Health Research, Inc. |
Compositions and methods for inhibiting hypoxia induced damage
|
|
EP3404116B1
(en)
*
|
2013-03-15 |
2022-10-19 |
The University of Chicago |
Methods and compositions related to t-cell activity
|
|
CN109652385A
(zh)
|
2013-04-20 |
2019-04-19 |
全国儿童医院研究所 |
外显子2靶向U7snRNA多核苷酸构建体的重组腺相关病毒递送
|
|
US10961531B2
(en)
*
|
2013-06-05 |
2021-03-30 |
Agex Therapeutics, Inc. |
Compositions and methods for induced tissue regeneration in mammalian species
|
|
US20160303047A1
(en)
|
2013-12-05 |
2016-10-20 |
Silence Therapeutics Gmbh |
Means for lung specific delivery
|
|
US11078462B2
(en)
|
2014-02-18 |
2021-08-03 |
ReCyte Therapeutics, Inc. |
Perivascular stromal cells from primate pluripotent stem cells
|
|
WO2015132303A1
(en)
|
2014-03-04 |
2015-09-11 |
Sylentis Sau |
Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
|
|
MY181586A
(en)
|
2014-05-19 |
2020-12-29 |
Pfizer |
Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr
|
|
TW201620526A
(zh)
|
2014-06-17 |
2016-06-16 |
愛羅海德研究公司 |
用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
|
|
US10240127B2
(en)
|
2014-07-03 |
2019-03-26 |
ReCyte Therapeutics, Inc. |
Exosomes from clonal progenitor cells
|
|
WO2016011324A2
(en)
|
2014-07-18 |
2016-01-21 |
Oregon Health & Science University |
5'-triphosphate oligoribonucleotides
|
|
EP3572516B1
(en)
|
2014-08-09 |
2024-11-20 |
The Research Institute at Nationwide Children's Hospital |
Methods and materials for activating an internal ribosome entry site in exon 5 of the dmd gene
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
AU2015346277B2
(en)
|
2014-11-12 |
2020-03-26 |
Centre Hospitalier Universitaire De Liège |
Treatment of hormonal disorders of growth
|
|
RU2563989C1
(ru)
*
|
2014-11-20 |
2015-09-27 |
Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) |
Композиция для подавления экспрессии гена цитокина интерлейкина-4
|
|
AU2016306275A1
(en)
|
2015-08-07 |
2018-02-08 |
Arrowhead Pharmaceuticals, Inc. |
RNAi therapy for Hepatitis B virus infection
|
|
CN115433707A
(zh)
|
2015-12-07 |
2022-12-06 |
再生疗法有限公司 |
用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
|
|
WO2017129763A1
(en)
|
2016-01-28 |
2017-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
|
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
TWI780046B
(zh)
*
|
2016-05-10 |
2022-10-11 |
國立大學法人東京醫科齒科大學 |
炎症促進因子表現抑制劑、其有效成分之篩選方法、對於該方法為有用之表現匣、診斷藥及診斷方法
|
|
US10036024B2
(en)
|
2016-06-03 |
2018-07-31 |
Purdue Research Foundation |
siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
|
|
EP3269732A1
(en)
*
|
2016-07-11 |
2018-01-17 |
Rhemastem SRLS |
Therapeutic medium for the treatment of cancer
|
|
JOP20170161A1
(ar)
|
2016-08-04 |
2019-01-30 |
Arrowhead Pharmaceuticals Inc |
عوامل RNAi للعدوى بفيروس التهاب الكبد ب
|
|
EP3315125A1
(en)
|
2016-10-31 |
2018-05-02 |
Silence Therapeutics (London) Ltd |
Lipid nanoparticle formulation
|
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
|
EP3551641A4
(en)
|
2016-12-08 |
2021-01-13 |
University of Utah Research Foundation |
STAUFEN1 AGENTS AND ASSOCIATED PROCESSES
|
|
MX2019008199A
(es)
|
2017-01-06 |
2019-11-25 |
Avidity Biosciences Llc |
Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
|
|
TW202436621A
(zh)
|
2017-01-10 |
2024-09-16 |
美商愛羅海德製藥公司 |
α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法
|
|
US11324820B2
(en)
|
2017-04-18 |
2022-05-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
|
|
AU2018254485B2
(en)
|
2017-04-19 |
2024-07-11 |
Bio-Path Holdings, Inc. |
P-ethoxy nucleic acids for IGF-1R inhibition
|
|
WO2018195250A1
(en)
*
|
2017-04-19 |
2018-10-25 |
Bio-Path Holdings, Inc. |
P-ethoxy nucleic acids for igf-1r inhibition
|
|
US20200199541A1
(en)
|
2017-06-16 |
2020-06-25 |
Imba - Institut Für Molekulare Biotechnologie Gmbh |
Blood vessel organoid, methods of producing and using said organoids
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
SG11202004097RA
(en)
|
2017-11-09 |
2020-06-29 |
Univ Nat Corp Tokyo Medical & Dental |
Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method
|
|
KR20250148679A
(ko)
|
2017-12-06 |
2025-10-14 |
어비디티 바이오사이언시스 인크. |
근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
|
|
CA3090305A1
(en)
*
|
2018-02-28 |
2019-09-06 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
|
|
US20210009711A1
(en)
*
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
JP2021527649A
(ja)
|
2018-06-14 |
2021-10-14 |
ユニバーシティー オブ ユタ リサーチ ファウンデーションＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｕｔａｈ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ |
Ｓｔａｕｆｅｎ１調節剤および関連する方法
|
|
CN108977445B
(zh)
*
|
2018-06-29 |
2021-05-25 |
山东农业大学 |
拟南芥microRNA400在调控植物耐镉性中的应用
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
US10857174B2
(en)
|
2018-07-27 |
2020-12-08 |
United States Government As Represented By The Department Of Veterans Affairs |
Morpholino oligonucleotides useful in cancer treatment
|
|
US11168141B2
(en)
|
2018-08-02 |
2021-11-09 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
WO2020028832A1
(en)
|
2018-08-02 |
2020-02-06 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating dystrophinopathies
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
WO2020033748A1
(en)
*
|
2018-08-08 |
2020-02-13 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
|
BR112021001613A2
(pt)
|
2018-08-13 |
2021-05-04 |
Alnylam Pharmaceuticals, Inc. |
agentes de ácido ribonucleico de fita dupla, célula, composições farmacêuticas, métodos de inibição da expressão gênica, de inibição da replicação e de tratar um sujeito, métodos para reduzir o nível de um antígeno e para reduzir a carga viral e uso de um agente de dsrna
|
|
KR102097794B1
(ko)
*
|
2018-09-17 |
2020-04-06 |
차의과학대학교 산학협력단 |
신규한 miRNA smR-167 및 폐암 예방 또는 치료를 위한 이의 용도
|
|
WO2020117715A1
(en)
|
2018-12-03 |
2020-06-11 |
Board Of Regents, The University Of Texas System |
Oligo-benzamide analogs and their use in cancer treatment
|
|
IL319265A
(en)
|
2018-12-21 |
2025-04-01 |
Avidity Biosciences Inc |
Anti-transferrin receptor antibodies and their uses
|
|
EP3959319A4
(en)
|
2019-04-25 |
2023-06-07 |
Avidity Biosciences, Inc. |
NUCLEIC ACID COMPOSITIONS AND METHODS FOR MULTI-EXON SKIPPING
|
|
WO2020225779A1
(en)
|
2019-05-09 |
2020-11-12 |
Istituto Pasteur Italia - Fondazione Cenci Bolognetti |
Rig-i agonists for cancer treatment and immunotherapy
|
|
US20230150926A1
(en)
|
2020-03-17 |
2023-05-18 |
Genevant Sciences Gmbh |
Cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
IL296387B2
(en)
|
2020-03-19 |
2024-08-01 |
Avidity Biosciences Inc |
Preparations and methods for the treatment of facial, back and arm muscle atrophy
|
|
MX2022011880A
(es)
|
2020-03-27 |
2022-10-20 |
Avidity Biosciences Inc |
Composiciones y metodos para tratar distrofia muscular.
|
|
EP4164656A4
(en)
*
|
2020-06-11 |
2025-10-22 |
Ionis Pharmaceuticals Inc |
COMPOUNDS AND METHODS FOR REDUCING MSH3 EXPRESSION
|
|
AU2021403156A1
(en)
|
2020-12-18 |
2023-07-13 |
Genevant Sciences Gmbh |
Peg lipids and lipid nanoparticles
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
KR20240055874A
(ko)
|
2021-09-16 |
2024-04-29 |
어비디티 바이오사이언시스 인크. |
안면견갑상완 근이영양증을 치료하는 조성물 및 방법
|
|
ES3017428T3
(en)
|
2022-01-31 |
2025-05-12 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
|
WO2023144792A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
|
|
KR20240163743A
(ko)
|
2022-03-28 |
2024-11-19 |
엠피리코 인크. |
변형된 올리고뉴클레오티드
|
|
US12071621B2
(en)
|
2022-04-05 |
2024-08-27 |
Avidity Biosciences, Inc. |
Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
|
|
AU2023254846A1
(en)
|
2022-04-15 |
2024-10-10 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and formulations for treating myotonic dystrophy
|
|
WO2024159113A1
(en)
*
|
2023-01-27 |
2024-08-02 |
The Methodist Hospital |
Modulators of alternative polyadenylation and methods of use thereof
|
|
WO2024215814A2
(en)
*
|
2023-04-10 |
2024-10-17 |
Anand Rene |
Methods and pharmaceutical compositions for treating aging
|
|
WO2025052278A1
(en)
|
2023-09-05 |
2025-03-13 |
Genevant Sciences Gmbh |
Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
|
|
WO2025133951A1
(en)
|
2023-12-21 |
2025-06-26 |
Genevant Sciences Gmbh |
Ionizable lipids suitable for lipid nanoparticles
|